Aandelen in “Gezondheidstechnologie”

Aandeel Datum Koers Evolutie
Even geduld...

Nieuws over “Gezondheidstechnologie”

18:00 · IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026 · Persbericht

18:00 · IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2026 · Persbericht

15:35 · Novo Nordisk A/S - share repurchase programme · Persbericht

14:00 · Boston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 results · Persbericht

14:00 · Novo Nordisk and AWS enter strategic partnership to accelerate drug discovery through AI · Persbericht

13:30 · Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio · Persbericht

13:30 · Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 · Persbericht

13:29 · Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments · Persbericht

13:04 · Aurora, a Global Leader in Medical Cannabis, Announces Results of 2026 Annual General Meeting · Persbericht

13:00 · BrewDog Claims London's Summer Park Season with ‘Park IPA’ · Persbericht

11:40 · Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 07 08 2026] - (CGWL) · Persbericht

10:52 · CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law · Persbericht

09:38 · ADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law · Persbericht

07:55 · AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million · Persbericht

9/08 · DEADLINE NEXT WEEK: Hagens Berman Advises ADMA Biologics, Inc. Investors to Contact the Firm Before August 10, 2026 · Persbericht

7/08 · INVESTOR NOTICE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - CAPR · Persbericht

7/08 · MONDAY INVESTOR DEADLINE: ADMA Biologics, Inc. (NASDAQ: ADMA) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit · Persbericht

7/08 · Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky · Persbericht

7/08 · Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update · Persbericht

7/08 · Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist · Persbericht

7/08 · Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments · Persbericht

Mijn selecties